Desoxycorticosterone Pivalate in Dogs

Desoxycorticosterone pivalate, often shortened to DOCP, is a prescription injectable medication used in dogs with primary hypoadrenocorticism, also called Addison’s disease. In this condition, the adrenal glands do not make enough mineralocorticoid hormone, especially aldosterone. That hormone helps the body hold on to sodium, excrete potassium, and maintain normal hydration and blood pressure. DOCP replaces that missing mineralocorticoid support and is one of the main long-term treatment options your vet may use.

DOCP does not replace cortisol. That matters because many dogs with primary Addison’s disease need both mineralocorticoid support and glucocorticoid support. In practice, this often means DOCP injections plus a separate glucocorticoid such as prednisone or prednisolone, especially during times of stress, illness, surgery, or travel. Your vet decides how much support your dog needs based on lab work, clinical signs, and how stable your dog is over time.

Most dogs receive DOCP by injection about every 25 to 30 days, although the exact dose and interval can vary. Early in treatment, bloodwork is a big part of success. Sodium, potassium, kidney values, hydration status, and your dog’s day-to-day symptoms help your vet fine-tune the plan. Some dogs do well on label doses, while others are managed with lower doses, longer intervals, or both.

For many pet parents, the biggest advantage of DOCP is consistency. Once a dog is stable, this medication can support a very good quality of life. The tradeoff is that it requires regular injections and monitoring. That makes it a medication that works best when pet parents and your vet can follow a clear long-term plan together.

DOCP is a mineralocorticoid replacement. In healthy dogs, aldosterone tells the kidneys to retain sodium and water while increasing potassium excretion. Dogs with primary Addison’s disease lose that signal, so sodium can drop, potassium can rise, and dehydration, weakness, low blood pressure, and collapse can follow. DOCP steps in to provide that missing mineralocorticoid effect.

After injection, DOCP helps the kidneys rebalance electrolytes over time. As sodium improves and potassium comes down, many dogs regain appetite, energy, and better hydration. Because these changes affect circulation and kidney function, your vet usually checks blood electrolytes after starting treatment and after dose changes. Monitoring is not optional with this medication. It is how your vet confirms that the dose is matching your dog’s needs.

An important detail is that DOCP is selective for mineralocorticoid activity. It does not provide meaningful glucocorticoid replacement. That is why many dogs still need prednisone or prednisolone, even when their sodium and potassium look good. If a dog is stressed, sick, or having surgery, your vet may adjust glucocorticoid support even if the DOCP plan stays the same.

This medication is approved for dogs with primary hypoadrenocorticism. It is not the right fit for every adrenal problem. Dogs with secondary hypoadrenocorticism may need glucocorticoid replacement without mineralocorticoid therapy, while dogs with atypical Addison’s may or may not need mineralocorticoid support at first. Your vet uses testing, including ACTH stimulation and electrolyte trends, to decide where DOCP fits.

Many dogs tolerate DOCP well, especially once the dose and interval are individualized. Mild effects can include soreness at the injection site, increased thirst, increased urination, or mild digestive upset. Some of these signs may also overlap with the glucocorticoid medication given alongside DOCP, so your vet may look at the full treatment plan rather than blaming one drug alone.

More important side effects usually relate to over- or under-replacement. If the dose is too high, a dog may retain too much sodium and water or lose too much potassium. If the dose is too low or the interval is too long, Addison’s signs can return. That can look like lethargy, vomiting, diarrhea, weakness, poor appetite, dehydration, or collapse. In other words, the biggest risk is often not a dramatic drug reaction but a mismatch between the dog’s needs and the current plan.

The product information advises caution in dogs with congestive heart failure, edema, severe kidney disease, or uncontrolled high blood pressure because mineralocorticoid therapy affects fluid and electrolyte balance. Dogs with these conditions may still have treatment options, but they need closer oversight. Your vet may recommend more frequent lab checks or a different strategy depending on the whole case.

See your vet immediately if your dog becomes weak, collapses, vomits repeatedly, has severe diarrhea, seems very dehydrated, or suddenly stops eating. Those signs can point to an Addisonian crisis or poor control of the disease, and they should not be monitored at home without veterinary guidance.

DOCP is given by injection, either under the skin or into the muscle, depending on the product and your vet’s protocol. Label dosing for Zycortal begins at 2.2 mg/kg, with reassessment around day 25 and later dose or interval adjustments based on sodium-to-potassium balance and the dog’s clinical response. In real-world practice, many dogs are eventually maintained on lower doses, longer intervals, or both, but those changes should be made only by your vet after monitoring.

At the start of treatment, monitoring is usually more frequent. VCA notes that electrolytes and kidney values are often checked every 10 to 14 days initially, then every 3 to 4 months once a dog is stable. Some dogs need rechecks sooner if they are newly diagnosed, recently hospitalized, changing dose, or showing any return of symptoms. Pet parents should expect the first few months to involve more lab work than the maintenance phase.

DOCP is usually only one part of the plan. Because it does not replace cortisol, many dogs also receive prednisone or prednisolone. Your vet may recommend a daily low dose, stress dosing during illness or travel, or another individualized plan. Never change or stop either medication on your own, even if your dog seems normal. Dogs with Addison’s can look well right up until they are not.

If your dog misses an injection appointment, contact your vet promptly. Do not wait for symptoms to appear. A delayed dose can let electrolytes drift out of range, and some dogs decompensate quickly. Keeping a calendar reminder for injections, lab checks, and refill dates is one of the most helpful things a pet parent can do.

DOCP is commonly used together with glucocorticoids, not instead of them. That combination is expected in many dogs with primary Addison’s disease. The main interaction concern is not a dangerous incompatibility between the drugs, but the way they can affect thirst, urination, appetite, blood pressure, and electrolyte interpretation. Your vet may adjust one medication after reviewing how the other is working.

Other medications can complicate monitoring. Diuretics, intravenous fluids, some blood pressure medications, and drugs that affect kidney function or electrolytes can change sodium and potassium values. That does not always mean they cannot be used together. It means your vet may need to time lab work carefully and interpret results in context.

Dogs with heart disease, kidney disease, or fluid retention deserve extra caution because mineralocorticoid therapy can influence circulating volume and electrolyte balance. If your dog sees more than one clinic, make sure every veterinarian knows your dog receives DOCP and any glucocorticoid medication. A full medication list should include prescription drugs, supplements, and any recent steroid exposure.

Pet parents should also mention if their dog has been treated for Cushing’s disease with drugs such as mitotane or trilostane, or has recently stopped long-term steroid therapy. Those histories can affect adrenal function and may change how your vet approaches diagnosis, monitoring, and long-term hormone replacement.